Document 0267
 DOCN  M9650267
 TI    Interleukin-2 therapy of Langerhans cell histiocytosis.
 DT    9605
 AU    Hirose M; Saito S; Yoshimoto T; Kuroda Y; Department of Pediatrics,
       Tokushima University School of; Medicine, Japan.
 SO    Acta Paediatr. 1995 Oct;84(10):1204-6. Unique Identifier : AIDSLINE
       MED/96157173
 AB    A 20-month-old girl was diagnosed with Langerhans cell histiocytosis on
       the basis of a seborrheic skin rash, multiple punched out bony lesions,
       and skin biopsy findings. Combination therapy including
       alpha-interferon, vincristine, vindesine, cyclophosphamide, etoposide,
       cisplatin, betamethasone, THP-adriamycin, cytarabine and methotrexate
       was ineffective. Because cyclophosphamide enhanced lesion growth within
       the skull, we administered an intravenous infusion of interleukin-2 with
       remarkable efficacy. The reduction in lesion size with interleukin-2
       treatment paralleled the increase in the percentage of CD16-positive
       natural killer cells in the peripheral blood.
 DE    Antineoplastic Agents, Combined/THERAPEUTIC USE  Case Report  CD4-CD8
       Ratio  Etoposide/ADMINISTRATION & DOSAGE  Female  Histiocytosis,
       Langerhans-Cell/IMMUNOLOGY/*THERAPY  Human  Infant
       Interleukin-2/*THERAPEUTIC USE  Killer Cells, Natural/IMMUNOLOGY
       Prednisolone/ADMINISTRATION & DOSAGE  Receptors, IgG/ANALYSIS  Remission
       Induction  Vindesine/ADMINISTRATION & DOSAGE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).